Showing results (161-170 of 183) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.The New England Journal of Medicine|January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancerHarry D Bear, Gong Tang, Priya Rastogi, et al.Breast Cancer Research and Treatment|September 3, 2020
Risk factors for inflammatory and non-inflammatory breast cancer in North AfricaCatherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.The Lancet. Oncology|June 19, 2012
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trialAlexander H G Paterson, Stewart J Anderson, Barry C Lembersky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])Charles E Geyer, Joanne L Blum, Greg Yothers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.Annals of Surgical Oncology|November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40Harry D Bear, Gong Tang, Priya Rastogi, et al.Journal of the National Cancer Institute|March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast CancerRim S Kim, Nan Song, Patrick G Gavin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2017
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)Joanne L Blum, Patrick J Flynn, Greg Yothers, et al.Pageof 19